Cargando…

Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP

The toolbox for genetic engineering has quickly evolved from CRISPR/Cas9 to a myriad of different gene editors, each with promising properties and enormous clinical potential. However, a major challenge remains: delivering the CRISPR machinery to the nucleus of recipient cells in a nontoxic and effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gustafsson, Oskar, Rädler, Julia, Roudi, Samantha, Lehto, Tõnis, Hällbrink, Mattias, Lehto, Taavi, Gupta, Dhanu, Andaloussi, Samir EL, Nordin, Joel Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232299/
https://www.ncbi.nlm.nih.gov/pubmed/34198625
http://dx.doi.org/10.3390/pharmaceutics13060878
_version_ 1783713608441528320
author Gustafsson, Oskar
Rädler, Julia
Roudi, Samantha
Lehto, Tõnis
Hällbrink, Mattias
Lehto, Taavi
Gupta, Dhanu
Andaloussi, Samir EL
Nordin, Joel Z.
author_facet Gustafsson, Oskar
Rädler, Julia
Roudi, Samantha
Lehto, Tõnis
Hällbrink, Mattias
Lehto, Taavi
Gupta, Dhanu
Andaloussi, Samir EL
Nordin, Joel Z.
author_sort Gustafsson, Oskar
collection PubMed
description The toolbox for genetic engineering has quickly evolved from CRISPR/Cas9 to a myriad of different gene editors, each with promising properties and enormous clinical potential. However, a major challenge remains: delivering the CRISPR machinery to the nucleus of recipient cells in a nontoxic and efficient manner. In this article, we repurpose an RNA-delivering cell-penetrating peptide, PepFect14 (PF14), to deliver Cas9 ribonucleoprotein (RNP). The RNP-CPP complex achieved high editing rates, e.g., up to 80% in HEK293T cells, while being active at low nanomolar ranges without any apparent signs of toxicity. The editing efficiency was similar to or better compared to the commercially available reagents RNAiMAX and CRISPRMax. The efficiency was thoroughly evaluated in reporter cells and wild-type cells by restriction enzyme digest and next-generation sequencing. Furthermore, the CPP-Cas9-RNP complexes were demonstrated to withstand storage at different conditions, including freeze-thaw cycles and freeze-drying, without a loss in editing efficiency. This CPP-based delivery strategy complements existing technologies and further opens up new opportunities for Cas9 RNP delivery, which can likely be extended to other gene editors in the future.
format Online
Article
Text
id pubmed-8232299
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82322992021-06-26 Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP Gustafsson, Oskar Rädler, Julia Roudi, Samantha Lehto, Tõnis Hällbrink, Mattias Lehto, Taavi Gupta, Dhanu Andaloussi, Samir EL Nordin, Joel Z. Pharmaceutics Article The toolbox for genetic engineering has quickly evolved from CRISPR/Cas9 to a myriad of different gene editors, each with promising properties and enormous clinical potential. However, a major challenge remains: delivering the CRISPR machinery to the nucleus of recipient cells in a nontoxic and efficient manner. In this article, we repurpose an RNA-delivering cell-penetrating peptide, PepFect14 (PF14), to deliver Cas9 ribonucleoprotein (RNP). The RNP-CPP complex achieved high editing rates, e.g., up to 80% in HEK293T cells, while being active at low nanomolar ranges without any apparent signs of toxicity. The editing efficiency was similar to or better compared to the commercially available reagents RNAiMAX and CRISPRMax. The efficiency was thoroughly evaluated in reporter cells and wild-type cells by restriction enzyme digest and next-generation sequencing. Furthermore, the CPP-Cas9-RNP complexes were demonstrated to withstand storage at different conditions, including freeze-thaw cycles and freeze-drying, without a loss in editing efficiency. This CPP-based delivery strategy complements existing technologies and further opens up new opportunities for Cas9 RNP delivery, which can likely be extended to other gene editors in the future. MDPI 2021-06-14 /pmc/articles/PMC8232299/ /pubmed/34198625 http://dx.doi.org/10.3390/pharmaceutics13060878 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gustafsson, Oskar
Rädler, Julia
Roudi, Samantha
Lehto, Tõnis
Hällbrink, Mattias
Lehto, Taavi
Gupta, Dhanu
Andaloussi, Samir EL
Nordin, Joel Z.
Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP
title Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP
title_full Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP
title_fullStr Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP
title_full_unstemmed Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP
title_short Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP
title_sort efficient peptide-mediated in vitro delivery of cas9 rnp
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232299/
https://www.ncbi.nlm.nih.gov/pubmed/34198625
http://dx.doi.org/10.3390/pharmaceutics13060878
work_keys_str_mv AT gustafssonoskar efficientpeptidemediatedinvitrodeliveryofcas9rnp
AT radlerjulia efficientpeptidemediatedinvitrodeliveryofcas9rnp
AT roudisamantha efficientpeptidemediatedinvitrodeliveryofcas9rnp
AT lehtotonis efficientpeptidemediatedinvitrodeliveryofcas9rnp
AT hallbrinkmattias efficientpeptidemediatedinvitrodeliveryofcas9rnp
AT lehtotaavi efficientpeptidemediatedinvitrodeliveryofcas9rnp
AT guptadhanu efficientpeptidemediatedinvitrodeliveryofcas9rnp
AT andaloussisamirel efficientpeptidemediatedinvitrodeliveryofcas9rnp
AT nordinjoelz efficientpeptidemediatedinvitrodeliveryofcas9rnp